Cognition Therapeutics, Inc. Common Stock
CGTX
CGTX: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
moreShow CGTX Financials
Recent trades of CGTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CGTX's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on CGTX's company Twitter account
Number of mentions of CGTX in WallStreetBets Daily Discussion
Recent insights relating to CGTX
Recent picks made for CGTX stock on CNBC
ETFs with the largest estimated holdings in CGTX
Flights by private jets registered to CGTX